![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 2022
October 13, 2022
Research results in breast and kidney cancer; recognition of key colleagues; and a sneak peek of the Fall 2022 Group Meeting
October 13, 2022
Health care administrator Charmaine Green shares her experience supporting cancer clinical trials and discusses how her role has evolved over the years
October 13, 2022
Eight early-career investigators will present their work; two will be selected to receive awards of distinction
October 13, 2022
This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
October 13, 2022
A Standing Main Member of ECOG-ACRIN since 1983
October 13, 2022
The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more